In pancreatic cancer, both fatostatin and PF429242 inhibit cell proliferation and the growth of xenograft tumor by reducing SREBP-1 and its downstream signaling cascades, such as FASN and SCD-1 (17). The gene discussed is SCD; the disease is neoplasm.